Colin B. Bier, Ph.D., Elected to Receptagen Ltd. Board of Directors.EDMONDS, WASHINGTON--(BUSINESS WIRE)--July 2, 1997--Receptagen Ltd.(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). RCG., OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. RCEPF.) Receptagen Ltd. today announced that Colin B. Bier bier n. 1. A stand on which a corpse or a coffin containing a corpse is placed before burial. 2. A coffin along with its stand: followed the bier to the cemetery. was elected to the Board of Directors at the Annual General Meeting of shareholders held on June 27, 1997. Dr. Bier was the nominee of choice by InterUnion Financial Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IUFC), who held the right to appoint a nominee when it completed the restructuring and recent financing of the Company earlier this year. Dr. Bier received his doctorate in experimental pathology from Colorado State University Colorado State University, at Fort Collins; land-grant with state and federal support; chartered 1870, opened 1879 as an agricultural college, assumed present name in 1957. There is a veterinary teaching hospital, an agricultural campus, and a research campus. in 1967 and has a distinguished academic background at various research institutions. For instance, he was a Postdoctoral Research Fellow at the Medical Research Council of Canada and participated in the Dr. Douglas James Fellowship in Pathology at McGill University in Montreal, Quebec. Currently, Dr. Bier is a consultant in Toxicology and Bioregulatory Affairs for ABA BioResearch Inc. in Montreal, Quebec. Previously, he was President and Chief Executive Officer of ITR Laboratories, Inc., a Quebec company, and Vice President and Director of the Division of Experimental Toxicology and Clinical Pathology for Bio-Research Laboratories Ltd. in Senneville, Quebec. He was also the Director of Laboratories and Research for Mount Sinai Hospital Mount Sinai Hospital can refer to:
Warren Wheeler, President and Chief Executive Officer of Receptagen stated, "The caliber of scientific expertise and business acumen that Dr. Bier brings to our Board is of significant importance to the Company. He is the first outside director elected to the board with both scientific and product development background which should help Receptagen secure and evaluate new merger and acquisition opportunities currently available to the Company." Receptagen recently closed a $2,500,000 CDN (Content Delivery Network) A system of distributed content on a large intranet or the public Internet in which copies of content are replicated and cached throughout the network. Special Warrants Offering through a corporate restructuring led by InterUnion Financial Corporation. Concurrently, the Company announced that it is considering a number of alternatives in the area of mergers and acquisitions and is evaluating a proposal to merge with Generex Pharmaceuticals, Inc., which is based in Toronto. Receptagen is actively involved in two operations in Edmonds, Washington: Receptagen Corporation, which is pursuing worldwide development of proprietary "Growth Blocker" drugs to induce apoptosis (programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the ) in cancer cells; and Ryan Pharmaceuticals Inc., which is developing drugs to prevent apoptosis of brain cells for stroke therapy and owns the exclusive rights to U.S. commercialization of Coenzyme Q10 (CoQ10) for use in treating AIDS symptoms. -0- The Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. has neither approved nor disapproved of the information contained herein. CONTACT: Receptagen Ltd. Warren Wheeler, 800/558-8846 or Joseph S. Baba, 800/558-8846 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion